Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 15.6 CNY, compared to the current stock price of 12.05 CNY [6]. Core Views - The company's performance in 2024 met expectations, with total revenue reaching 30.063 billion CNY, a year-on-year increase of 9.24%, and net profit attributable to shareholders of 1.327 billion CNY, up 52.92% year-on-year [2][3]. - The company benefits from a steady growth in its core earthmoving machinery business and a strong export performance, with domestic sales growth outpacing industry averages [2][4]. - The company has implemented a three-pronged strategy that has enhanced its growth potential and operational efficiency [2]. Summary by Sections Product Segmentation - Earthmoving machinery generated revenue of 17.941 billion CNY, up 12.79% year-on-year, with domestic market share increasing by 1.3 percentage points and export revenue accounting for nearly 60% [3]. - Other engineering machinery and components achieved revenue of 9.079 billion CNY, a 2.96% increase year-on-year, with significant growth in mining machinery and high-altitude machinery exports [3]. - Prestressed machinery revenue reached 2.517 billion CNY, up 12.23% year-on-year, with notable increases in order amounts and overseas revenue [3]. Market Segmentation - Domestic revenue was 16.302 billion CNY, a 1.53% increase year-on-year, while overseas revenue reached 13.76 billion CNY, up 20.05% year-on-year, with emerging markets showing over 30% growth [4]. - The company's gross margin and net margin improved to 22.5% and 4.61%, respectively, driven by structural optimization and cost control measures [4]. Financial Projections - The company aims for a revenue target of 34.6 billion CNY in 2025, with net profit projected to reach 2.11 billion CNY, reflecting a growth rate of 58.9% [10]. - Revenue forecasts for 2025-2027 are 34.83 billion CNY, 40.85 billion CNY, and 48.79 billion CNY, with corresponding growth rates of 15.8%, 17.3%, and 19.4% [10][12]. - The projected PE ratios for the same period are 11.5X, 8.3X, and 6X, indicating a favorable valuation outlook [10].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 22.59 CNY, compared to the current stock price of 20.56 CNY [6]. Core Insights - The company achieved a revenue of 6.032 billion CNY in 2024, representing a year-on-year growth of 16.44%, and a net profit of 1.549 billion CNY, which is a 39.58% increase year-on-year [1]. - The gross margin improved to 54.70%, up by 3.94 percentage points year-on-year, with a net profit margin of 35.02%, an increase of 5.88 percentage points year-on-year [2]. - The company expanded its plasma collection capabilities, achieving a total collection of 2,781 tons, a 15.15% increase year-on-year, maintaining a 20% market share in the domestic industry [3]. - Significant progress was made in the R&D pipeline, with multiple products advancing through clinical trials and receiving regulatory approvals, which will support the company's long-term growth [4]. Summary by Sections Financial Performance - In 2024, the company reported a revenue of 6.032 billion CNY and a net profit of 1.549 billion CNY, with respective year-on-year growth rates of 16.44% and 39.58% [1]. - The gross margin for 2024 was 54.70%, an increase of 3.94 percentage points, while the net profit margin reached 35.02%, up by 5.88 percentage points [2]. Operational Developments - The company completed the acquisition of 100% of Zhongyuan Ruide for 1.85 billion USD, enhancing its production capacity and expanding its network of plasma collection stations to 107 across 16 provinces [3]. - The operational plasma collection stations collected 2,781 tons of plasma in 2024, marking a 15.15% increase year-on-year [3]. Research and Development - The company made notable advancements in its R&D efforts, with several products completing clinical trials and receiving approvals, including the subcutaneous human immunoglobulin and recombinant coagulation factors [4]. - The orderly progress of the R&D pipeline is expected to provide strong support for the company's medium to long-term development [4].

Investment Rating - The investment rating for Hisense Visual is maintained at "Buy-A" with a target price of 27.80 CNY for the next six months [4]. Core Views - Hisense Visual reported a revenue of 58.53 billion CNY for 2024, representing a year-over-year increase of 9.2%. The net profit attributable to shareholders was 2.25 billion CNY, up 7.2% year-over-year. In Q4 alone, the company achieved a revenue of 17.88 billion CNY, a significant increase of 24.3% year-over-year, and a net profit of 0.94 billion CNY, which is a remarkable growth of 100.1% year-over-year [1][2][3]. Summary by Sections Financial Performance - In Q4, Hisense's domestic television sales increased by 14% year-over-year, driven by the "old-for-new" policy stimulating demand in the television industry. The company's global market share for television shipments reached 13.9%, an increase of 1.0 percentage points year-over-year [2]. - The net profit margin for Q4 was 5.2%, reflecting a year-over-year increase of 2.0 percentage points, primarily due to improved gross margins from high-end products and stable panel costs [2][3]. Cash Flow - The operating cash flow for Q4 increased by 100 million CNY year-over-year, attributed to rapid revenue growth. Cash received from sales and services rose by 340 million CNY year-over-year [3]. Future Outlook - The company is expected to benefit from ongoing product structure optimization and rapid growth in new display businesses, which include laser display, commercial display, cloud services, and chip businesses. EPS forecasts for 2025, 2026, and 2027 are 1.99 CNY, 2.19 CNY, and 2.45 CNY, respectively [3][4].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 39.80 CNY per share, maintaining the rating [5]. Core Views - The company's Q4 2024 performance met expectations, with revenue of 599.4 billion CNY, a year-on-year increase of 12%, and a quarter-on-quarter increase of 18%. The net profit attributable to shareholders was 22.6 billion CNY, also up 12% year-on-year but down 32% quarter-on-quarter [1]. - The overall sales volume in Q4 was 380,000 units, reflecting a 30% increase quarter-on-quarter and a 4% increase year-on-year, primarily driven by government subsidy policies [2]. - The company is entering a new growth phase, with new vehicle launches expected to drive sales upward, particularly in the mainstream market [4]. Summary by Sections Financial Performance - For the full year 2024, the company achieved revenue of 2,022 billion CNY, a 17% increase year-on-year, and a net profit of 127 billion CNY, an 81% increase year-on-year [1]. - The average selling price (ASP) for vehicles in Q4 was 157,000 CNY, up 11,000 CNY year-on-year, attributed to a higher proportion of premium models [2]. - The overall gross margin for Q4 was 19.1%, a year-on-year increase of 0.6 percentage points, while the domestic gross margin for 2024 is expected to be 19.9%, up 4.4 percentage points year-on-year [3]. Market Outlook - The company is expected to benefit from the launch of new models, including the second-generation Xiaolong MAX and new models from Haval and Wey, which are anticipated to drive domestic sales growth [4]. - The Hi4Z technology is expected to enhance the company's competitive edge in the off-road vehicle market, potentially expanding its customer base and increasing profitability [4]. - The company has a diverse product lineup and strong technological reserves, indicating significant export potential as new models and powertrain types are introduced [4].

Investment Rating - The report maintains an investment rating of "Outperform the Market-A" for the media industry [6]. Core Insights - The media industry is expected to benefit from the AI wave and the trend of consumer IP, leading to a new narrative that reshapes production methods and a new round of prosperity, enhancing both supply vitality and capacity [3][48]. - The report identifies four main directions for "AI to C": hardware entry, phenomenal applications, blockbuster content, and IP operation, indicating that both culture and communication will be reshaped by AI [1][43]. Summary by Sections 1. Mobile Internet Era: Transition from Culture and Communication to Content and Distribution - The flow logic is being disrupted, leading to a collapse of traditional flow models [9][10]. - The transition from PGC to UGC has significantly enriched the supply side of content [44]. 2. Four Core Ecological Positions in the Mobile Internet Era to C - The four core ecological positions identified are hardware entry, phenomenal applications, blockbuster content, and IP operation [16][28]. 3. AI Era: Increasing Barriers in Content Distribution and Communication - AI is expected to reshape the production process, enhance supply-side vitality, and elevate the importance of distribution channels [43][47]. 4. New Narrative of Content Industry from the Perspective of Media Internet - The content industry faces challenges due to traditional production methods and a lack of industrialization [44]. - AI is anticipated to significantly improve production efficiency and reduce costs, particularly in high-value roles like top actors and directors [47]. 5. Investment Recommendations - The report suggests focusing on companies such as Bona Film Group, Wanda Film, Mango Excellent Media, and others, as they are likely to benefit from the trends identified [3][52].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 20.8 CNY per share [6]. Core Views - The report highlights a positive outlook on the company's profit improvement trend due to increased production and efficiency in electrolytic aluminum [1][9]. - The company achieved a revenue of 54.45 billion CNY in 2024, representing a year-on-year increase of 27.61%, and a net profit of 4.41 billion CNY, up 11.52% year-on-year [1]. - The report anticipates a growth in electrolytic aluminum production to approximately 3.01 million tons in 2025, an increase of 310,000 tons compared to the 2024 target [8][9]. Summary by Sections Financial Performance - In Q4 2024, the company reported a revenue of 15.27 billion CNY, a quarter-on-quarter increase of 5.00%, but a net profit of 592 million CNY, which is a significant decrease of 59.21% quarter-on-quarter [1][2]. - The average price of aluminum in 2024 was 19,972 CNY per ton, a 6.7% increase year-on-year, while the average price of alumina rose by 39.7% to 4,053 CNY per ton [8]. Production and Efficiency - The company's aluminum production for 2024 was 2.9383 million tons, a year-on-year increase of 22.45%, with Q4 production remaining stable at 790,300 tons [8]. - The report indicates that the company is focusing on increasing production efficiency and optimizing its asset structure, having made a provision for asset impairment of 327 million CNY in 2024 [8][9]. Dividend Policy - The company plans to distribute a cash dividend of 1.8 CNY per 10 shares (including tax), totaling 624 million CNY, with an annual cumulative dividend reaching 1.42 billion CNY, resulting in a dividend payout ratio of 32% [4].

Investment Rating - The report maintains an investment rating of "Buy-A" for the company, with a 6-month target price of HKD 57.32 [5][4]. Core Insights - The company reported a revenue of HKD 94.2 billion for 2024, representing a year-on-year growth of 51.8%, with product revenue reaching HKD 82.3 billion, up 43.6% [1]. - The company is advancing its PD-1/IL-2 dual antibody IBI363, which is expected to showcase updated proof-of-concept data at the 2025 ASCO conference and initiate multiple registration clinical studies in 2025 [2]. - The company aims to achieve product revenue of HKD 20 billion by 2027, demonstrating strong confidence in the growth of its innovative drug portfolio [3]. Financial Projections - Revenue projections for the company are estimated at HKD 118.96 billion, HKD 157.49 billion, and HKD 199.78 billion for the years 2025, 2026, and 2027 respectively, with corresponding net profits of HKD 6.50 billion, HKD 17.75 billion, and HKD 28.78 billion [4][10]. - The company anticipates that five of its pipelines will enter global multi-center phase 3 clinical trials by 2030, indicating a robust pipeline for future growth [3]. Market Position and Strategy - The company is focusing on internationalization, with IBI363 positioned as a cornerstone drug for next-generation immuno-oncology therapies, highlighting its potential for overseas licensing [2]. - The company plans to launch several key products, including IBI311 and a GLP-1R/GCGR dual-target peptide product, which are expected to contribute significantly to revenue growth [3].

Group 1 - The report indicates that the domestic fiscal revenue for January-February has weakened, with public fiscal revenue declining by 1.6% year-on-year, and tax revenue down by 3.9% [2] - The report highlights that the first half of April is likely to see a continuation of the "high-cut low" trend, with a focus on low-position cyclical relative returns and high-dividend absolute returns [2][4] - The report notes that the technology sector has shown signs of overheating, with the TMT index's trading volume dropping from around 50% to 27% [4][32] Group 2 - The report identifies industries with clear signs of improvement, including insurance, industrial metals, and optical electronics, with over half of the stocks in these sectors seeing upward revisions in earnings forecasts [60] - It also points out that while overall industry improvement may not be significant, sectors like batteries, photovoltaic equipment, and semiconductors have a considerable number of stocks with potential for exceeding expectations [60] - The report emphasizes that the overall improvement in industry sentiment may be concentrated among leading companies in sectors such as military electronics and engineering machinery [60] Group 3 - The report suggests that the high-dividend assets in the Hong Kong market have seen a significant increase, with the premium over A-share dividends reaching a three-year low [27][30] - It highlights that the performance of the TMT index in April has historically been poor, with only a 14.3% chance of outperforming the CSI 300 index [57] - The report indicates that the upcoming earnings reports in April are expected to show significant performance from sectors with improving earnings forecasts [60]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [7]. Core Insights - The report highlights that several newly included innovative drugs in the medical insurance directory are rapidly entering hospitals, with some drugs exceeding 100 hospital entries [2][19]. - The report notes a significant increase in the number of new drug approvals and applications, with 103 new drug INDs approved and 43 new drug INDs accepted this week [3][21]. Summary by Sections Weekly New Drug Market Review - From March 24 to March 28, 2025, the top five companies in the new drug sector by stock price increase were Youzhiyou (37.30%), Maibo Pharmaceutical (33.33%), Keji Pharmaceutical (26.44%), Yiming Anke (18.68%), and Zhixiang Jintai (18.34%). The top five companies with the largest declines were Kaituo Pharmaceutical (-23.84%), Tengshengbo Pharmaceutical (-16.32%), WuXi AppTec (-15.17%), Yongtai Biological (-12.56%), and Yunding Xinyao (-11.41%) [1][15]. Key Analysis of the New Drug Industry - The National Medical Insurance Administration updated the hospital entry data for innovative drugs included in the medical insurance directory as of the end of February 2025. Notable drugs that have entered over 100 hospitals include: - Cardunilumab from Kangfang Biopharmaceutical - Budesonide enteric-coated capsules from Yunding Xinyao - Goserelin microspheres from BeiGene/Green Leaf - Tolebrutinib from Innovent Biologics - Cangrelor and Clopidogrel from Haishi Pharmaceutical - Benzyl benzoate from Xinlitai - Dazatinib from Jingxin Pharmaceutical [2][19]. New Drug Approval & Acceptance Status - This week, 103 new drugs were approved for IND, 43 new drug INDs were accepted, and 5 new drug NDAs were accepted [3][21]. Domestic New Drug Industry Focus - Key developments include: - On March 21, Heptares Therapeutics announced a global strategic collaboration with AstraZeneca for the development of next-generation multispecific antibody therapies targeting immune diseases and tumors. - On March 24, Federated Pharmaceutical announced an exclusive licensing agreement with Novo Nordisk for the global development, production, and commercialization rights of the long-acting GLP-1R/GIPR/GCGR triple agonist UBT251. - On March 25, Heng Rui Medicine announced an exclusive licensing agreement with Merck for the development, production, and commercialization rights of the Lp(a) oral small molecule project (including the lead compound HRS-5346) outside Greater China [4][12]. Overseas New Drug Industry Focus - Key developments include: - On March 27, Daiichi Sankyo registered a phase III clinical trial for DS-8201 (T-DXd) in combination with Keytruda for first-line treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). - On March 27, AstraZeneca registered a phase 1/2 clinical trial for AZD0120 for the treatment of recurrent systemic lupus erythematosus, with an expected enrollment of 150 patients. - On March 28, Lexicon Pharmaceuticals entered into an exclusive licensing agreement with Novo Nordisk for the global development, production, and commercialization rights of the oral small molecule inhibitor LX9851 [12].

Investment Rating - The investment rating for Midea Group is "Buy-A" with a 6-month target price of 90.40 CNY, compared to the current stock price of 76.87 CNY [6]. Core Views - Midea Group reported a revenue of 409.08 billion CNY for 2024, representing a year-over-year increase of 9.5%, and a net profit attributable to shareholders of 38.54 billion CNY, up 14.3% year-over-year [2]. - The company maintains a high-quality balance sheet, which positions it well to navigate external challenges in 2025 while continuing to achieve steady growth [2]. - Midea's overseas sales grew at a robust pace, with a year-over-year increase of 10.8% in the second half of 2024, while domestic sales benefited from national subsidies, showing a growth of 6.9% [3]. - The company is expected to enhance its overseas OBM business investments, leading to sustained growth in international revenue [3]. - Midea's Q4 2024 net profit margin increased by 0.3 percentage points year-over-year, driven by significant investment-related income [4]. - The company reported a net cash flow from operating activities of 60.51 billion CNY for 2024, which is 1.6 times its net profit attributable to shareholders [5]. Financial Summary - Midea's 2024 revenue is projected to reach 409.08 billion CNY, with net profit expected to be 38.54 billion CNY, and earnings per share (EPS) forecasted at 5.03 CNY [12]. - The company anticipates a revenue growth rate of 8.7% for 2025, with net profit growth of 11.5% [17]. - The net profit margin is expected to improve gradually, reaching 10.2% by 2027 [12]. - Midea's total assets are projected to be 577.25 billion CNY in 2025, with a debt-to-equity ratio of 134.8% [17]. - The company plans to distribute a cash dividend of 35 CNY per 10 shares for 2024, which represents 69.3% of its net profit [5].